QNCX - Quince Therapeutics, Inc.
1.27
-0.100 -7.874%
Share volume: 1,707,213
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.37
-0.10
-0.07%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-13-2024 | 11-13-2024 | 03-24-2025 | 05-13-2025 | 08-11-2025 | 11-12-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 8.673 M | 8.842 M | 8.546 M | 10.109 M | 12.934 M | 9.895 M | 11.364 M | |
| Selling general and admin | 4.971 M | 4.695 M | 3.630 M | 4.284 M | 4.789 M | 3.342 M | 3.281 M | |
| Research and development | 3.702 M | 4.147 M | 4.916 M | 5.825 M | 8.145 M | 6.553 M | 8.083 M | |
| Total expenses | 11.218 M | 28.192 M | 5.863 M | 12.012 M | 14.858 M | 10.427 M | 13.430 M | |
| 151.31% | -79.20% | 104.88% | 23.69% | -29.82% | 28.80% | |||
| Operating income | -11.218 M | -28.192 M | -5.863 M | -12.012 M | -14.858 M | -10.427 M | -13.430 M | |
| Ebit | -11.617 M | -28.101 M | -5.713 M | -12.530 M | -14.945 M | -15.792 M | -13.788 M | |
| Pretax income | -11.118 M | -27.693 M | -5.479 M | -12.451 M | -14.983 M | -15.982 M | -13.488 M | |
| 149.08% | -80.22% | 127.25% | 20.34% | 6.67% | -15.61% | |||
| Income tax | 31.000 K | 36.000 K | 13.000 K | 7.000 K | 47.000 K | 67.000 K | -46.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -11.149 M | -27.729 M | -5.492 M | -12.458 M | -15.030 M | -16.049 M | -13.442 M | |
| -148.71% | 80.19% | -126.84% | -20.65% | -6.78% | 16.24% |